Evidence map›Paper›PMID 38939222›Full record

ArticleFrontiers in psychology2024

Longitudinal follow-up of metformin treatment in Fragile X Syndrome.

Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in psychology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Panhaneath Seng *MIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Federica Alice Maria Montanaro *Child and Adolescent Neuropsychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Hazel Maridith Barlahan BiagMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Maria Jimena Salcedo-ArellanoMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Kyoungmi KimMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Matthew Dominic PonziniMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Flora TassoneMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Andrea SchneiderMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Leonard AbbedutoMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Angela John ThurmanMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
David HesslMIND Institute, University of California Davis Health System, Sacramento, CA, United States.
Francois V BolducDepartment of Pediatrics, Department of Medical Genetics, Women and Children Health Research Institute, University of Alberta, Edmonton, AB, Canada.
Sebastien JacquemontCHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada.
Sarah LippéCHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada.
Randi J HagermanMIND Institute, University of California Davis Health System, Sacramento, CA, United States.

Funding

Research Project: Pathologic Significance of Maternal AutoantibodiesP50HD103526 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEONARD J. ABBEDUTO, Melissa Dawn Bauman · 2020 to 2026
$9.7M
NICHD NIH HHS P50 HD103526
6 · The paper itself

Abstract

Introduction: Metformin has been used as a targeted treatment to potentially improve cognition and slow the typical IQ decline that occurs during development among individuals with fragile X syndrome (FXS). In this follow-up study, we are following the trajectory of IQ and adaptive behavior changes over 1 to 3 years in individuals with FXS who are clinically treated with metformin in an open label trial. Method: Individuals with FXS ages 6 to 25 years (mean 13.15 ± 5.50) and nonverbal IQ mean 57.69 (±15.46) were treated for 1-3 years (1.88 ± 0.63). They all had a baseline IQ test using the Leiter-III non-verbal cognitive assessment and the Vineland-III adaptive behavior assessment before the start of metformin. Repeat Leiter-III and Vineland-III were completed after at least 1 year of metformin (500-1,000 mg/dose given twice a day). Result: There were no significant changes in non-verbal IQ or in the adaptive behavior measurements at FDR < 0.05. The findings thus far indicate that both IQ and adaptive behavior are stable over time, and we did not see a significant decline in either measure. Conclusion: Overall, the small sample size and short follow-up duration limit the interpretation of the effects of metformin on cognitive development and adaptive functioning. There is individual variability but overall for the group there was no significant decline in IQ or adaptive behavior.

Indexed as

adaptive behaviorfragile X syndromeIQlongitudinal follow-upmetformintreatment

Identifiers

PMID38939222
PMCPMC11210589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.